Home Tags Telisotuzumab Vedotin

Tag: Telisotuzumab Vedotin

Photo: AbbVie R&D has focused on developing biologics. In particular, antibody therapeutics have been proven to be clinically effective for disease areas such as oncology and immunology. Photo courtesy: © 2019 - 2020 AbbVie

ASCO 2024: AbbVie to Showcases Robust Solid Tumor Pipeline with New...

New data from AbbVie's innovative antibody-drug conjugate (ADC) platform will be showcased across three oral presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting (May 31 - June 4, 2024).

Creating A Strong ADC Pipeline: AbbVie Agrees to Acquires ImmunoGen for...

Creating A Strong ADC Pipeline: AbbVie Agrees to Acquires ImmunoGen for $10.1 Billion

Phase 2 LUMINOSITY Study Shows Positive Results for Telisotuzumab Vedotin in...

Phase 2 LUMINOSITY Study Shows Positive Results for Telisotuzumab Vedotin in for Patients with Previously Treated Non-Small Cell Lung Cancer

AbbVie and Bristol-Myers Squibb Evaluate Telisotuzumab Vedotin and Nivolumab in c-Met...

A new clinical trial collaboration between AbbVie and Bristol-Myers Squibb Company will evaluate the combination of AbbVie's investigational antibody-drug conjugate telisotuzumab vedotin also known...

X